The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy

(2010) K H T Paraiso et al.   BRITISH JOURNAL OF CANCER

BRAF, a target in melanoma

(2010) Keith T. Flaherty et al.   CANCER

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

(2010) H. Yang et al.   CANCER RESEARCH

Targeting Multiple Kinase Pathways: A Change In Paradigm

(2010) L. Gossage et al.   CLINICAL CANCER RESEARCH

CSPG4 in Cancer: Multiple Roles

(2010) X. Wang et al.   CURRENT MOLECULAR MEDICINE

CSPG4 Protein as a New Target for the Antibody-Based Immunotherapy of Triple-Negative Breast Cancer

(2010) Xinhui Wang et al.   JNCI-Journal of the National Cancer Institute

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

(2010) Gideon Bollag et al.   NATURE

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

(2010) Cory M. Johannessen et al.   NATURE

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells

(2010) Ruth Halaban et al.   Pigment Cell & Melanoma Research

Epidemiology of invasive cutaneous melanoma

(2009) R. M. MacKie et al.   ANNALS OF ONCOLOGY

Integrating BRAF/MEK inhibitors into combination therapy for melanoma

(2009) K S M Smalley et al.   BRITISH JOURNAL OF CANCER

Melanoma Proteoglycan Modifies Gene Expression to Stimulate Tumor Cell Motility, Growth, and Epithelial-to-Mesenchymal Transition

(2009) J. Yang et al.   CANCER RESEARCH

Phosphorylated 4E-BP1 Is Associated with Poor Survival in Melanoma

(2009) K. E. O'Reilly et al.   CLINICAL CANCER RESEARCH

Immunotherapy of Malignant Disease with Tumor Antigen-Specific Monoclonal Antibodies

(2009) M. Campoli et al.   CLINICAL CANCER RESEARCH

Structure and Regulation of the Versican Promoter

(2009) Clelia Domenzain-Reyna et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Factors underlying sensitivity of cancers to small-molecule kinase inhibitors

(2009) Pasi A. Jänne et al.   NATURE REVIEWS DRUG DISCOVERY

Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma

(2008) C. Montagut et al.   CANCER RESEARCH